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Open Forum Infectious Diseases
MAJOR ARTICLE

Predictors of Mortality Among a National Cohort of
Veterans With Recurrent Clostridium difficile Infection
Haley J. Appaneal,1,2,3 Aisling R. Caffrey,1,2,3,4 Maya Beganovic,1,2 Sanja Avramovic,5 and Kerry L. LaPlante1,2,3,6
Infectious Diseases Research Program, Providence Veterans Affairs Medical Center, Providence, Rhode Island; 2College of Pharmacy, University of Rhode Island, Kingston, Rhode Island; 3Center
of Innovation in Long-Term Support Services, Providence Veterans Affairs Medical Center, Providence, Rhode Island; 4Brown University School of Public Health, Providence, Rhode Island; 5Health
Administration and Policy, George Mason University, Fairfax, Virginia; 6Division of Infectious Diseases, Warren Alpert Medical School of Brown University, Providence, Rhode Island

Background. Though recurrent Clostridium difficile infection (CDI) is common and poses a major clinical concern, data are
lacking regarding mortality among patients who survive their initial CDI and have subsequent recurrences. Risk factors for mortality
in patients with recurrent CDI are largely unknown.
Methods. Veterans Affairs patients with a first CDI (stool sample with positive C. difficile toxin(s) and ≥2 days CDI treatment)
were included (2010–2014). Subsequent recurrences were defined as additional CDI episodes ≥14 days after the stool test date and
within 30 days of the end of treatment. A matched (1:4) case–control analysis was conducted using multivariable conditional logistic
regression to identify predictors of all-cause mortality within 30 days of the first recurrence.
Results. Crude 30-day all-cause mortality rates were 10.6% for the initial CDI episode, 8.3% for the first recurrence, 4.2% for the
second recurrence, and 5.9% for the third recurrence. Among 110 cases and 440 controls, 6 predictors of mortality were identified:
use of proton pump inhibitors (PPIs; odds ratio [OR], 3.86; 95% confidence interval [CI], 2.14–6.96), any antibiotic (OR, 3.33; 95%
CI, 1.79–6.17), respiratory failure (OR, 8.26; 95% CI, 1.71–39.92), congitive dysfunction (OR, 2.41; 95% CI, 1.02–5.72), nutrition
deficiency (OR, 2.91; 95% CI, 1.37–6.21), and age (OR, 1.04; 95% CI, 1.01–1.07).
Conclusions. In our national cohort of Veterans, crude mortality decreased by 44% from the initial episode to the third recurrence. Treatment with antibiotics, use of PPIs, and underlying comorbidities were important predictors of mortality in recurrent
CDI. Our study assists health care providers in identifying patients at high risk of death after CDI recurrence.
Keywords. Clostridium difficile infection; mortality; predictors; recurrent disease; Veterans Affairs.

Clostridium difficile is a gram-positive, anaerobic, spore-forming bacterium that causes infectious diarrhea ranging in
severity from mild to life-threatening [1]. Disease recurrence
and decreased survival are important concerns related to
Clostridium difficile infection (CDI). It is estimated that C. difficile is responsible for at least half a million cases of infection
in the United States annually [2]. The estimated number of
first recurrences of CDI each year is 83 000, and the estimated
number of deaths is 29 300 [2]. Symptomatic first recurrence
after resolution of the primary CDI episode occurs in 20%–
30% of patients, usually within 30 days after treatment cessation [3–5]. Clostridium difficile infection mortality estimates
vary widely in the literature, with rates ranging from less than
5% to more than 20% in severe cases [6, 7]. A review of 27
studies found that the CDI-associated mortality rate was 6%
within 3 months of diagnosis [8]. Previous work has identified
several risk factors for mortality in patients with CDI [9–12].
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Older age, non-CDI antibiotic use concomitantly or after CDI
treatment, and presence of underlying comorbid conditions
are among the most frequently reported mortality risk factors
[9, 10].
Despite the common and growing concern of recurrent disease over the past decade, data are lacking regarding mortality
rates among patients who survive their initial CDI episode and
have subsequent recurrences [5]. The few previously reported
mortality estimates among those with disease recurrence vary
widely from approximately 5% to greater than 35%, likely due
to the different patient populations studied and significant
variations in follow-up for death from 30 days to 1 year postrecurrence [13–16]. Moreover, although some studies suggest that recurrence may increase risk of death, others suggest
that recurrence may not increase risk of death and mortality
rates may actually decrease as recurrences accrue [13, 15–18].
Finally, independent predictors of mortality among patients
with CDI recurrence are largely unknown. Knowledge of these
factors could improve the management of patients with recurrent disease and limit unfavorable outcomes. Thus, we sought
to describe crude mortality rates of subsequent CDI episodes
and identify independent predictors of mortality among our
national cohort of Veterans with recurrence of Clostridium difficile infection.
Predictors of Poor Outcomes in Recurrent CDI • OFID • 1
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METHODS
Data Sources

We used data from national Veterans Affairs (VA) databases for
this work. Corporate Data Warehouse (CDW), Medical SAS,
and Decision Support System (DSS) data were accessed through
the VA Informatics and Computing Infrastructure (VINCI).
Our cohort included patients from 128 VA facilities nationally.
We developed a national cohort of adult Veterans (≥18 years)
with an initial CDI episode (no CDI episodes in the year prior)
treated during an inpatient admission or outpatient encounter
at a VA facility from May 1, 2010, to December 30, 2014. We
defined a CDI episode as a positive stool sample for C. difficile
toxin(s) and receipt of at least 2 days of standard CDI treatment
(oral [PO] or intravenous [IV] metronidazole, PO or rectal [PR]
vancomycin, or fidaxomicin) [1, 19]. Use of a minimum treatment window of at least 2–3 days of CDI therapy (regardless of
dosing frequency) has been used previously in several studies
for CDI identification and minimum CDI treatment exposure
[17, 20, 21]. Although a CDI testing method was not available in
the data source, the use of the nucleic acid amplification test for
CDI diagnostic testing among VA facilities has increased from
33% in 2010 to 54% in 2012 to 81% in 2015 [22]. The initial
episode was the first episode of CDI during the study period.
First recurrence, second recurrence, and third recurrence were
defined as subsequent CDI episodes at least 14 days after the
positive stool test date and within 30 days of the end of treatment of the prior occurrence [23–25]. An interval of at least
14 days is commonly used to distinguish new recurrent episodes from prior CDI episodes [2, 26].
Study Design

We described the all-cause mortality rate by episode number.
Mortality was defined as death from any cause within 30 days
of the end date of CDI treatment of the prior CDI episode. We
also conducted a case–control analysis in our cohort of patients
with a first recurrence of CDI to identify independent predictors of all-cause mortality. Cases were defined as patients who
died from any cause within 30 days of the end of treatment of
recurrence. Controls were survivors at 30 days from the end
of treatment of recurrence and were matched to cases on year,
facility, and severity. Four controls were matched to each case.
Clostridium difficile infection severity was defined as severe
if the closest white blood cell count was >15 × 103/μL or the
serum creatinine was >1.5 g/dL within 7 days of CDI treatment,
nonsevere if the white blood cell count was ≤15 × 103/μL and
the serum creatinine was ≤1.5 g/dL, or unknown otherwise
[27]. In our overall cohort of patients with CDI, >96% of white
blood cell count (n = 42 298) and serum creatinine (n = 40 261)
levels were obtained within 2 days of treatment.
Potential predictors assessed were based on clinical relevance and/or previously described predictors of poor outcomes
2 • OFID • Appaneal et al

Statistical Analysis

We calculated descriptive statistics, including number, percentage, mean (standard deviation), and median (interquartile
range). Differences in clinical characteristics and crude mortality rates by episode number were analyzed using the chi-square
test or Fisher exact test for categorical data and the Student t test
or Wilcoxon rank-sum test for continuous data, as appropriate.
We also analyzed differences between cases and controls and
used backward, manual, stepwise conditional logistic regression
to identify independent predictors of mortality [33]. All variables with a P value of less than .10 from univariate analysis were
included in subsequent multivariable analysis [33]. Variables
were then removed in a stepwise fashion from the multivariable models until all remaining variables were significantly associated with the outcome (P < .05) [33]. Multicollinearity was
assessed using the correlation matrix of the final model and variance inflation factor values [33, 34]. All variables in our final
multivariable model had a variance inflation factor value of <3,
indicating lack of multicollinearity. All statistical analyses were
performed with SAS (version 9.2; SAS Institute Inc., Cary, NC).
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Study Population

[1, 28–31]. Potential predictors included demographics,
treatment characteristics, current comorbidities and medical history, aggregate comorbidity burden using the Charlson
Comorbidity Index, laboratory results, current and previous
health care exposures, and concurrent and previous medication
exposures. We defined CDI treatment as metronidazole PO or
IV monotherapy, vancomycin PO or PR monotherapy, vancomycin and metronidazole combination therapy, or fidaxomicin
alone or in combination with vancomycin and/or metronidazole. We compared metronidazole monotherapy with all other
treatment options due to the high frequency of metronidazole
monotherapy in our cohort. International Classification of
Diseases, 9th Revision (ICD-9), diagnosis and procedure codes
were used to identify the presence of current and previous disease states and procedures. Current comorbidities were defined
as disease states that occurred during the index CDI admission
(inpatient) or 30 days before the CDI episode (outpatient) and
medical histories were defined as those that occurred in the year
before the CDI episode. Clinical Classifications Software (CCS)
for ICD-9 codes was used to categorize diagnoses and procedures into broader disease states [32]. Medication exposures
assessed included antibiotics, gastric acid suppressants, immunosuppressants, laxatives, and supplemental medications (probiotics, binding agents, rifampin, rifaximin, nitazoxanide, and
bacitracin). Medication exposures were assessed before CDI
treatment (30 days prior for immunosuppressants and antibiotics and 7 days for gastric acid suppressants, histamine receptor 2
antagonists [H2RA], or proton pump inhibitors [PPIs]), during
CDI treatment, and 30 days after CDI treatment. The window
for assessment of exposure to medications was selected based
on clinical relevance or previous work [3, 9, 31].

The Institutional Review Board and the Research and
Development Committee of the Providence Veterans Affairs
Medical Center approved this study protocol before the study
was initiated.
RESULTS

DISCUSSION

This study is the first to identify independent predictors of
mortality among a national cohort of Veterans who already
experienced an initial and subsequent first recurrence of CDI.
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We identified 49 064 initial episodes of CDI, 2521 episodes of
first recurrence, 409 episodes of second recurrence, and 68
episodes of third recurrence over our 5-year study period. The
mean age of patients with an initial CDI episode (SD) was 66.2
(14.1) years. Mean age (SD) increased with each subsequent
occurrence: 68.5 (13.1) years for first recurrence, 70.7 (13.4)
years for second recurrence, and 73.2 (13.9) years for third
recurrence. The majority of initial episodes (69.7%, n = 34 177)
were treated in the outpatient setting. Significantly more episodes were treated in the outpatient setting for the initial episode
as compared with the first recurrence (58%, n = 1462); however,
with each subsequent recurrence, the percentage of patients
treated in the outpatient setting remained stable (56.5% second
recurrence, 55.9% third recurrence). Thirty-four percent of initial CDI episodes were severe (n = 16 806). The severity of most
cases of recurrence was unknown (95.1% first, 97.6% second,
100% third recurrence). The crude 30-day all-cause mortality
rate was 10.6% for the initial episode (n = 5214), 8.3% for first
recurrence (n = 208), 4.2% for second recurrence (n = 17), and
5.9% for third recurrence. Crude 30-day all-cause mortality was
significantly higher for the initial episode vs first recurrence
(P < .001) and first recurrence vs second recurrence (P = .004).
We identified 110 cases who died within 30 days of end of
treatment of the first recurrence and 440 surviving controls
matched on year, facility, and severity. Characteristics of cases
and controls are described in Table 1. The mean age (SD) of cases
was 73.1 (12.5) years, and that of controls was 66.9 (13.1) years.
Treatment in the outpatient setting (49.1% cases vs 65.0% controls) and metronidazole monotherapy treatment (40.9% cases
vs 71.4% controls) were less common in cases as compared with
controls. Table 2 lists the 6 independent predictors of 30-day allcause mortality identified. Medication exposures predictive of
mortality included use of proton pump inhibitors within 7 days
before CDI treatment (odds ratio [OR], 3.86; 95% confidence
interval [CI], 2.14–6.96) and any non-CDI antibiotic use during
CDI treatment (OR, 3.33; 95% CI, 1.79–6.17). For comorbidities and medical history, current respiratory failure (OR, 8.26;
95% CI, 1.71–39.92), current congitive dysfunction (OR, 2.41;
95% CI, 1.02–5.72), and medical history of nutrition deficiency
(OR, 2.91; 95% CI, 1.37–6.21) were predictive of mortality. Age
was also a predictor of mortality (OR, 1.04; 95% CI, 1.01–1.07).

Although several prior studies have studied the risk factors for
mortality in patients with CDI, to our knowledge, ours is the
first to focus specifically on evaluating predictors of mortality
in patients with a first recurrence of CDI. From the time of
the first recurrence of CDI (second CDI episode per patient),
we followed patients to determine whether they died and then
identified predictors of death.
In addition to identifying predictors, our study described
crude mortality rates by subsequent episode. Our results are
supported by another recent VA analysis among 30 326 VHA
beneficiaries nationally, which also found higher 30-day mortality rates among those with initial disease (21%) than those
with recurrent disease (11% with first recurrence and 7% with
second recurrence) [35]. Another study among 1527 adults
diagnosed with CDI in a hospital in Canada described decreasing mortality rates with subsequent CDI episodes (10.9% initial, 7.6% first recurrence, 7.0% second recurrence, 5.7% third
recurrence) [16]. Possible explanations for decreased mortality
with recurrent disease include a survival bias among patients
who survive an initial episode, earlier disease detection and
treatment among those who recur as compared with those with
initial disease, and host-adaptive immune response changes
[35]. Another possible explanation for findings may be related
to the difficulties in distinguishing symptomatic recurrent CDI
from those with alternative etiologies for continued diarrhea.
A retrospective review of 117 patients referred for treatment
for presumed recurrent CDI found that 25% did not actually
have CDI but had an alterative diagnosis, usually postinfectious
inflammatory bowel syndrome [36].
Similar to our findings, previous studies have demonstrated
that older age and comorbid conditions are independent risk
factors for mortality in patients with CDI [9, 11, 12]. A systematic review that included 30 studies demonstrated that increasing age and underlying comorbid conditions, including both
individual conditions (specifically malignancy, chronic renal
failure, and coronary artery disease) and aggregate Charlson
score, were among the most commonly reported risk factors for
mortality in patients with CDI [9]. One of the major reasons
for an increased risk of poor outcomes, including mortality, in
older patients and/or those with serious comorbid conditions
may be a decreased ability to mount an adequate immune
response to the C. difficile toxin [37]. Age has been recognized
as a risk factor for both development of CDI and CDI-related
death [28]. A recent study that used the US 2011 Nationwide
Inpatient Sample (NIS) database and included more than 77 000
CDI hospitalizations found that progressive increase in age was
an independent predictor of CDI-associated in-hospital mortality, especially in patients age 81–100 years (OR, 4.12; 95%
CI, 3.39–4.99) as compared with those age 18–40 years [38].
Previous work evaluating predictors of complicated CDI (death,
need for colectomy, shock, perforation, or megacolon within
30 days) in patients diagnosed in a hospital in Quebec, Canada,

Table 1.

Patient Characteristics, 30-Day All-Cause Mortality
Cases With 30-d All-Cause
Mortality (n = 110)

Controls Without 30-d
All-Cause Mortality (n = 440)

Age, mean (SD), yc

73.1 (12.5)

66.9 (13.1)

Male gender, n (%)

109 (99.1)

419 (95.2)

80 (72.7)

326 (74.1)

White race, n (%)
Hispanic ethnicity, n (%)

23 (5.2)
180 (40.9)

Acute care

46 (41.8)

140 (31.8)

Long-term care

10 (9.1)

14 (3.2)

Outpatient

54 (49.1)

286 (65.0)

Metronidazole PO/IV monotherapy

45 (40.9)

314 (71.4)

Metronidazole monotherapy

45 (40.9)

314 (71.4)

PO monotherapy

28 (25.5)

251 (57.0)
63 (14.3)

Treatment setting, n (%)c

CDI treatment, n(%)c

IV monotherapy

17 (15.5)

Vancomycin PO monotherapy

26 (23.6)

74 (16.8)

Metronidazole PO/IV & vancomycin PO

39 (35.5)

50 (11.4)

CDI treatment duration, median (IQR), d

7 (11–4)

8 (4–15)

Charlson comorbidity score, median (IQR)c

3 (0–5)

1 (0–4)

Current comorbidities, n (%)a
Abdominal pain
Alcoholic disorder
Atherosclerosis
Bacterial infection (unspecified site)
Cerebrovascular disease

<5
8 (7.3)
15 (13.6)
8 (7.3)
<5

27 (6.1)
26 (5.9)
61 (13.9)
34 (7.7)
8 (1.8)

Chronic renal disease

21 (19.1)

63 (14.3)

Chronic obstructive pulmonary disease

16 (14.5)

58 (13.2)

Diabetes mellitus

12 (10.9)

70 (15.9)

6 (5.5)

25 (5.9)

Esophageal disorder
Fever of unknown origin

<5

14 (3.2)

Heart failurec

21 (19.1)

Hypertension

24 (21.8)

96 (21.8)

Liver disease

9 (8.2)

22 (5.0)

Myocardial infarction
Nutrition deficiencyc

<5
20 (18.2)

Osteoarthritis

<5

Peptic ulcer disease

<5

Peripheral vascular disease
Pulmonary heart diseasec

5 (4.5)

49 (11.1)

6 (1.4)
23 (5.2)
10 (2.3)
<5
18 (4.1)

8 (7.3)

9 (2.0)

Respiratory failurec

18 (16.4)

16 (3.6)

Solid organ cancer

16 (14.5)

49 (11.1)

6 (5.5)

12 (2.7)

8 (7.3)

50 (11.4)

Surgery/medical complication
Medical history, n (%)b
Abdominal pain
Alcoholic disorder

10 (9.1)

43 (9.8)

Atherosclerosisc

38 (34.5)

104 (23.6)

Bacterial infection (unspecified site)

20 (18.2)

76 (17.3)

Cognitve dysfunctionc

21 (19.1)

30 (6.8)

Cerebrovascular disease

6 (5.5)

17 (3.9)

Chronic renal disease

27 (24.5)

87 (19.8)

Chronic obstructive pulmonary disease

30 (27.3)

95 (21.6)

Diabetes mellitus

28 (25.5)

126 (28.6)

Esophageal disorder

24 (21.8)

82 (18.6)

6 (5.5)

29 (6.6)

Fever of unknown origin
Heart failurec

30 (27.3)

78 (17.7)

Hypertension

55 (50.0)

181 (41.1)

Liver disease

17 (15.5)

46 (10.5)
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7 (6.4)
48 (43.6)

Married, n (%)

Table 1.

Continued
Cases With 30-d All-Cause
Mortality (n = 110)

Controls Without 30-d
All-Cause Mortality (n = 440)

Myocardial infarction

5 (4.5)

14 (3.2)

Nutrition deficiencyc

30 (27.3)

39 (8.9)

Osteoarthritis

13 (11.8)

40 (9.1)

Peptic ulcer disease
Peripheral vascular disease

12 (2.7)

11 (10.0)

49 (11.1)

7 (6.4)

21 (4.8)

Solid organ cancer

26 (23.6)

72 (16.4)

Surgery/medical complication

14 (2.7)

36 (8.2)

Non-CDI antibiotic use, 30 d before Clostridium difficile
infection treatmentc

93 (84.5)

314 (71.4)

Non-CDI antibiotic use, during Clostridium difficile infection
treatmentc

82 (74.5)

213 (48.4)

Non-CDI antibiotic use, 30 d after Clostridium difficile infection treatment

36 (32.7)

154 (35.0)

Histamine receptor 2 antagonist use, 7 d before Clostridium
difficile infection treatment

11 (10.0)

28 (6.4)

Proton pump inhibitor use, 7 d before Clostridium difficile
infection treatmentc

68 (61.8)

156 (35.5)

7 (6.4)

49 (11.1)

42 (38.2)

165 (37.5)

5 (4.6)

36 (8.2)

13 (11.8)

55 (12.5)

Hospitalization, prior 90 d, n (%)

88 (80.0)

342 (77.7)

Long-term care admission, prior 90 d, n (%)c

11 (10.0)

20 (4.6)

Recurrent CDI in hospital setting, n (%)

57 (51.8)

155 (35.2)

Length of stay, median (IQR), dc

13 (8–21)

Medication exposures, n (%)

Histamine receptor 2 antagonist use, 30 d after Clostridium
difficile infection treatment
Proton pump inhibitor use, 30 d after Clostridium difficile
infection treatment
Probiotic use, 30 d after Clostridium difficile infection
treatment
Immunosuppressant use, 30 d after Clostridium difficile
infection treatment

7 (4–13)

Current comorbidities and medical histories were defined using Clinical Classification Software
for ICD-9.
Abbreviations: CDI, Clostridium difficile infection; IQR, interquartile range; IV, intravenous; PO, oral.
a

Current comorbidities were defined as diagnoses that occurred during the index CDI admission (inpatient) or 30 days before the CDI episode (outpatient).

b

Medical histories were defined as diagnoses that occurred in the year before the CDI episode.

c

P < .05.

during 1991–2005 with first recurrence identified older age as a
strong predictor [14].
Several comorbid conditions have been previously identified
as predictors of mortality in patients with CDI [13, 38]. Our
work demonstrated that respiratory failure, cognitive dysfunction, and nutrition deficiency were all independent predictors of
mortality. Respiratory failure has been previously identified as
an independent predictor of mortality in patients with fulminant
C. difficile colitis [39]. Intensive care unit admission and acute
renal failure were among the among the strongest predictors of
CDI-associated in-hospital mortality identified in the study of
CDI hospitalizations using 2011 NIS data, and although we did
not identify these conditions as independent predictors, respiratory failure may represent a related surrogate marker [38].
Functional decline has previously been associated with severe
CDI, and dependency in activities of daily living has been associated with long-term mortality in very old patients with CDI

[40, 41]. The diagnosis codes for cognitive dysfunction include
delirium, dementia, and amnestic and other cognitive disorders [32]. To our knowledge, nutrition deficiency has not been
previously identified as an independent predictor; however,
conditions that may cause or be related to various nutrition
deficiencies have been identified as independent predictors
of mortality, such as enteral tube feeding and inflammatory
bowel disease [38, 42, 43]. Although enteral tube feeding and
inflammatory bowel disease are not included in the codes
for nutrition deficiency, nutrition deficiency codes capture a
broad spectrum of nutritional conditions, such as unspecified
protein-calorie malnutrition, other malnutrition, cachexia,
and vitamin deficiencies [32]. It is possible that some enteral
tube feeding diets may lead to nutrition deficiencies in the
colon and resultant disruption on the colonic microbiota [42].
Additionally, the mortality risk has consistently been shown to
be higher in CDI patients with inflammatory bowel disease, a
Predictors of Poor Outcomes in Recurrent CDI • OFID • 5
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Pulmonary heart disease

5 (4.5)

Table 2.

Independent Predictors of 30-Day All-Cause Mortality

Predictor

Adjusted Odds Ratio

Lower 95% Confidence Limit

Upper 95% Confidence Limit

2.14

6.96

3.33

1.79

6.17

8.26

1.71

39.92

Medications used before Clostridium difficile infection treatment
Proton pump inhibitor (within 7 d before)

3.86

Concurrent medications used during Clostridium difficile infection treatment
Any antibiotica
Current comorbidities

Nutrition deficiency

2.91

1.37

6.21

Cognitve dysfunction

2.41

1.02

5.72

1.04

1.01

1.06

Demographics
Ageb

Adjusted odds ratios are estimated from multivariate analysis of the data. The final multivariate logistic regression model included 11 variables, including all predictive variables listed in
the table above (odds ratio >1) and also the following variables with odds ratios <1: clindamycin use within 30 days before Clostridium difficile infection treatment, histamine receptor 2
antagonist use within 30 days after Clostridium difficile infection treatment, medical history of respiratory failure, metronidazole monotherapy for Clostridium difficile infection vs all other
treatments, and treatment duration.
a
Any antibiotic included any antibiotic not used for the treatment of Clostridium difficile infection, including the following antibiotic classes/agents: aminoglycosides, aztreonam, β-lactam/
β-lactamase inhibitor combinations, carbapenems, cephalosporins, clindamycin, fluoroquinolones, fosfomycin, glyco-/glycolipo-/lipopeptdes (except vancomycin oral/rectal), nitrofurantoin,
macrolides, oxazolidinones, penicillins, polymyxins, sulfamethoxazole/trimethoprim, quinupristin-dalfopristin, tetracyclines, and tigecycline.
b

Age represents a discrete variable for each year of age.

population at risk for a number of nutrition deficiencies [38,
43].
Although several individual conditions were associated with
CDI, aggregate comorbidity burden was not identified as an
independent predictor. Most previous work has identified the
Charlson Comorbidity Index as an independent predictor of
mortality; however, similar to our findings, other studies have
not identified the Charlson Comorbidity Index as an independent predictor of mortality or poor outcomes [9, 42, 44].
The performance of aggregate comorbidity scores in predicting mortality is largely dependent on the underlying characteristics of the population under study [45, 46]. Additionally,
scores developed specifically to predict risk of death associated
with CDI have been found to outperform Charlson comorbidity scores. As such, future work developing such a score in the
Veteran population is warranted [38].
Another potential factor associated with mortality supported by our findings is continued disruption in the normal
colonic microbiota [37]. We found that concurrent use of any
non-CDI antibiotic and use of proton pump inhibitors within
7 days before CDI treatment were independent risk factors for
mortality. Antibiotic use is a well-established risk factor for the
development of incident and recurrent CDI, and there is also
evidence of an association between continued non-CDI antibiotic use and poor outcomes in patients with CDI [10, 47–50].
Continued use of antibiotics following CDI diagnosis (OR, 2.01;
95% CI, 1.01–3.99) was the strongest predictor of complicated
CDI (death or need for colectomy within 30 days after CDI
onset) identified in a hospital-based study [10]. In a single study
among 421 patients at an academic, urban, tertiary care hospital in the United States, longer courses of antibiotics during
the index CDI hospitalization were significantly associated with
6 • OFID • Appaneal et al

mortality within 180 days [13]. It is important to note that ongoing non-CDI active antibiotic therapy may be necessary and
unavoidable in patients with concomitant infections in addition
to their CDI, and both infections together may increase their
risk of death. There are several studies that link PPI use with
CDI recurrence, and there is even limited evidence that gastric acid suppression is associated with increased odds of death
in patients with CDI [9, 51]. However, PPIs are commonly
given to patients who are severely ill, have a number of serious
comorbid conditions, and are frequently exposed to antibiotics
[10, 52]. The effect of PPIs on death may differ depending on
these factors.
There are limitations to this work. Our definition of CDI does
not distinguish between symptomatic episodes and asymptomatic carriage. We attempted to include only patients treated
for CDI by requiring at least 2 days of standard CDI treatment [17, 20, 21]. In an attempt to include the most severely
ill patients who could not tolerate any medications by mouth,
we included patients treated with intravenous metronidazole
only [1]. Additionally, accurate identification of recurrent disease from administrative data is very challenging [53]. Previous
work has shown that the performance of diagnosis codes, laboratory data, or medication data used alone to accurately identify
recurrent disease was poor, and performance only improved
moderately when used in combination [53]. We were unable to
perform chart reviews to confirm the diagnosis of CDI recurrence in our cohort. Our work is thus limited in that we are not
able to determine if the reduction in crude mortality rates that
we observed among those with recurrences was due to continued symptoms of diarrhea due to alterative etiologies, such as
postinfectious inflammatory bowel syndrome, vs true recurrent
infection. Another limitation is that we are unable to account
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CONCLUSIONS

In our national cohort of Veterans with CDI, crude mortality
decreased by 44% from the initial episode to the third recurrence. Treatment with antibiotics, use of PPIs, and underlying
comorbidities were important predictors of mortality within
30 days of the end of treatment of CDI recurrence. Our data are
among the first to investigate predictors of mortality in patients
with an initial episode and subsequent recurrence and will
assist health care providers in identifying patients at high risk of
mortality after a first recurrence of CDI.
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